COUR Pharmaceuticals is a cutting-edge biotech company based in Northbrook, IL, dedicated to developing groundbreaking therapies that reprogram the immune system to achieve antigen-specific tolerance for immune-mediated diseases. Their unique platform of immune-modifying nanoparticles aims to treat the root cause of immune diseases, going beyond symptom management by avoiding toxic immune suppression.
With a focus on reprogramming the immune system and inducing tolerance to specific antigens while preserving immune functionality, COUR Pharmaceuticals has already made significant strides in the field. Their lead product, developed in partnership with Takeda, has successfully demonstrated the induction of antigen-specific immune tolerance in celiac disease, marking a major breakthrough in autoimmune disease treatment. Through their nanoparticle platform, COUR Pharmaceuticals envisions addressing a wide range of immune and inflammatory conditions, offering hope for patients worldwide.
Generated from the website
